May 5, 2021 7:37am

Pre-open indications:  2 BUY, 1 SELL and 1 Maintain SELL

Earnings: AxoGen (AXGN), Editas Medicine (EDIT), Fate Therapeutics (FATE), Global Blood Therapeutics (GBT), Regenxbio (RGNX), Vericel (VCEL)

Mentions: BSTG, CRSP, NTLA, RENE.L

My version of the morning’s “indications” is written to be informative; it’s what could happen or will materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  

Dow futures are UP +0.16% (+54 points), S&P futures are UP +0.28% (+12 points) and NASDAQ futures are UP +0.51% (+69 points)

 

U.S. stock futures rebounded on Wednesday

European stocks bounced upward

Asia-Pacific stocks were mostly subdued after a stateside sell-off in stocks, with major markets in China and Japan still closed for holidays.

 

Data Docket: Private payroll data will also be released at 8:15 a.m. ET. Economists are expecting 800,000 private jobs added in April, compared to the 517,000 in March, according to ADP. These numbers come ahead of Friday’s closely-watched jobs report. Two key readings on the services sector will also be released.

 

Henry’omics:

A positive open was in the cards after …

The S&P 500 wiped out Monday’s gains, dropping 0.7%; the Dow ended the day up about 20 points after dropping more than 300 points at one point on Tuesday.

The small-cap benchmark Russell 2000 fell 1.3%.

 

Q1/21 Earnings: three (3) yesterday <posted>: six (6) today

 https://www.regmedinvestors.com/articles/11628

 

Tuesday’s evening’s recap: “sector pukes most upsides; it wasn’t a cough but, more than reflux from newest market highs” … https://www.regmedinvestors.com/articles/11895

  • The Nasdaq closed DOWN -261.61 points (-1.88%);
  • The IBB closed down -2.84% and XBI closed down -3.84%
  • Sector volume was LOW with 1 of the 2-upside having higher than the 3-month average volume with the volume of 11 of 32-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +1.17 points or +6.39% at 19.48;
  • Tuesday’s percentage (%) of the 2-upside were +1.01% (BLUE) to +5.05% (RENE.L) while the 32-downside ranges from -0.67% (AXGN) to -15.85% (BLFS);

Q2/21:

May:  2 negative closes

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

Earnings:

  • Thursday – Athersys (ATHX), Caladrius Biosciences (CLBS)

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Biostage (BSTG): Questions continue … Maintaining Sell

Biostage (BSTG) closed down -$0.14 to $1.12 with 249 shares traded after Monday’s flat at $1.26 with 476 shares traded after Friday’s $1.26 with 1,009 shares traded, Thursday’s $1.26 with3,302 shares traded and last Wednesday’s -$0.02 to $1.26 with 830 shares traded.

Question#1: Why is BSTG still viable with a ‘going concerns” label, measured by continual losses, development failures, filed INDs with NO clinical trial initiated and continuous inflated financings if they are now able to execute past warrants and any thoughts of an even newer private placement?

Question#2: Isn’t it a broken company, with a “spent” cash position in a recent Q4/20 - having reported LATE with yet another part-time financial officer the fourth (4th) in two (2) years?

Question#3:  Does its status speak to the facts of inexcusable CURRENT management incompetence?

Question#4: With only $1 million left in the “till” WHAT is the runway with a “spend” and “net cash in operations of $4 million during the year ended 12/ 31/20”. Don’t forget the PPP loan remaining as DEBT ($0.4 million).

MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications, from what I discern are in store:

BUY on Bounce:

  • CRISPR Indication (CRSP) closed down -$7.08 to $115.73 after Monday’s -$8.46 to $122.81 after Friday’s -$0.61 to $131.27, Thursday’s -$3.66 and last Wednesday’s +$2.50 with a positive +$1.17 or +1.01% pre-market indication.
  • ReNeuron (RENE.L) closed up +$7.00 and has a positive indication of +$7.58 or +5.21% pre-market indication.

Maintaining SELL:

  • Intellia Therapeutics (NTLA) closed down-$1.80 to $72.00 after Monday’s -$2.97 to $73.80, Friday’s -$3.31 to $76.77, Thursday’s -$5.23 to $80.58 and last Wednesday’s $85.31 with a negative -$2.50 or -3.47% pre-market indication.

 

The BOTTOM LINE: New month, an even newer share pricing “battle” due to earnings’ season reporting.

Investor expectations are NOT high during this sector earnings’ season.

I haven’t been wrong in seeing trouble ahead in the markets and any prognostication could be somewhat difficult or unpleasant.

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see some lows that could be in the “pick-up” stock game.

I say, re-asses your risk as some questionable earnings are on the horizon.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.